These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 11754593)

  • 1. Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.
    Wada CK; Holms JH; Curtin ML; Dai Y; Florjancic AS; Garland RB; Guo Y; Heyman HR; Stacey JR; Steinman DH; Albert DH; Bouska JJ; Elmore IN; Goodfellow CL; Marcotte PA; Tapang P; Morgan DW; Michaelides MR; Davidsen SK
    J Med Chem; 2002 Jan; 45(1):219-32. PubMed ID: 11754593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.
    Tamura Y; Watanabe F; Nakatani T; Yasui K; Fuji M; Komurasaki T; Tsuzuki H; Maekawa R; Yoshioka T; Kawada K; Sugita K; Ohtani M
    J Med Chem; 1998 Feb; 41(4):640-9. PubMed ID: 9484512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design of selective and soluble inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).
    Rabinowitz MH; Andrews RC; Becherer JD; Bickett DM; Bubacz DG; Conway JG; Cowan DJ; Gaul M; Glennon K; Lambert MH; Leesnitzer MA; McDougald DL; Moss ML; Musso DL; Rizzolio MC
    J Med Chem; 2001 Nov; 44(24):4252-67. PubMed ID: 11708926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biaryl ether retrohydroxamates as potent, long-lived, orally bioavailable MMP inhibitors.
    Michaelides MR; Dellaria JF; Gong J; Holms JH; Bouska JJ; Stacey J; Wada CK; Heyman HR; Curtin ML; Guo Y; Goodfellow CL; Elmore IB; Albert DH; Magoc TJ; Marcotte PA; Morgan DW; Davidsen SK
    Bioorg Med Chem Lett; 2001 Jun; 11(12):1553-6. PubMed ID: 11412979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The evolution of the matrix metalloproteinase inhibitor drug discovery program at abbott laboratories.
    Wada CK
    Curr Top Med Chem; 2004; 4(12):1255-67. PubMed ID: 15320725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structure-activity relationships.
    Duan JJ; Chen L; Wasserman ZR; Lu Z; Liu RQ; Covington MB; Qian M; Hardman KD; Magolda RL; Newton RC; Christ DD; Wexler RR; Decicco CP
    J Med Chem; 2002 Nov; 45(23):4954-7. PubMed ID: 12408705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and synthesis of a series of (2R)-N(4)-hydroxy-2-(3-hydroxybenzyl)-N(1)- [(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide derivatives as potent, selective, and orally bioavailable aggrecanase inhibitors.
    Yao W; Wasserman ZR; Chao M; Reddy G; Shi E; Liu RQ; Covington MB; Arner EC; Pratta MA; Tortorella M; Magolda RL; Newton R; Qian M; Ribadeneira MD; Christ D; Wexler RR; Decicco CP
    J Med Chem; 2001 Oct; 44(21):3347-50. PubMed ID: 11585439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of stromelysin-1 (MMP-3) by P1'-biphenylylethyl carboxyalkyl dipeptides.
    Esser CK; Bugianesi RL; Caldwell CG; Chapman KT; Durette PL; Girotra NN; Kopka IE; Lanza TJ; Levorse DA; MacCoss M; Owens KA; Ponpipom MM; Simeone JP; Harrison RK; Niedzwiecki L; Becker JW; Marcy AI; Axel MG; Christen AJ; McDonnell J; Moore VL; Olszewski JM; Saphos C; Visco DM; Hagmann WK
    J Med Chem; 1997 Mar; 40(6):1026-40. PubMed ID: 9083493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors.
    Xue CB; Chen XT; He X; Roderick J; Corbett RL; Ghavimi B; Liu RQ; Covington MB; Qian M; Ribadeneira MD; Vaddi K; Trzaskos J; Newton RC; Duan JJ; Decicco CP
    Bioorg Med Chem Lett; 2004 Sep; 14(17):4453-9. PubMed ID: 15357971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery and characterization of the potent, selective and orally bioavailable MMP inhibitor ABT-770.
    Curtin ML; Florjancic AS; Heyman HR; Michaelides MR; Garland RB; Holms JH; Steinman DH; Dellaria JF; Gong J; Wada CK; Guo Y; Elmore IB; Tapang P; Albert DH; Magoc TJ; Marcotte PA; Bouska JJ; Goodfellow CL; Bauch JL; Marsh KC; Morgan DW; Davidsen SK
    Bioorg Med Chem Lett; 2001 Jun; 11(12):1557-60. PubMed ID: 11412980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of a novel series of selective MMP inhibitors: identification of the gamma-sulfone-thiols.
    Freskos JN; Mischke BV; DeCrescenzo GA; Heintz R; Getman DP; Howard SC; Kishore NN; McDonald JJ; Munie GE; Rangwala S; Swearingen CA; Voliva C; Welsch DJ
    Bioorg Med Chem Lett; 1999 Apr; 9(7):943-8. PubMed ID: 10230616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and structure-activity relationship of alpha-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.
    Aranapakam V; Grosu GT; Davis JM; Hu B; Ellingboe J; Baker JL; Skotnicki JS; Zask A; DiJoseph JF; Sung A; Sharr MA; Killar LM; Walter T; Jin G; Cowling R
    J Med Chem; 2003 Jun; 46(12):2361-75. PubMed ID: 12773041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beta-aryl-succinic acid hydroxamates as dual inhibitors of matrix metalloproteinases and tumor necrosis factor alpha converting enzyme.
    Kottirsch G; Koch G; Feifel R; Neumann U
    J Med Chem; 2002 May; 45(11):2289-93. PubMed ID: 12014967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of antiangiogenic and antitumor efficacy of N-biphenyl sulfonyl-phenylalanine hydroxiamic acid (BPHA), an orally-active, selective matrix metalloproteinase inhibitor.
    Maekawa R; Maki H; Yoshida H; Hojo K; Tanaka H; Wada T; Uchida N; Takeda Y; Kasai H; Okamoto H; Tsuzuki H; Kambayashi Y; Watanabe F; Kawada K; Toda K; Ohtani M; Sugita K; Yoshioka T
    Cancer Res; 1999 Mar; 59(6):1231-5. PubMed ID: 10096553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and structure-activity relationships of beta- and alpha-piperidine sulfone hydroxamic acid matrix metalloproteinase inhibitors with oral antitumor efficacy.
    Becker DP; Villamil CI; Barta TE; Bedell LJ; Boehm TL; Decrescenzo GA; Freskos JN; Getman DP; Hockerman S; Heintz R; Howard SC; Li MH; McDonald JJ; Carron CP; Funckes-Shippy CL; Mehta PP; Munie GE; Swearingen CA
    J Med Chem; 2005 Oct; 48(21):6713-30. PubMed ID: 16220987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent, selective, orally bioavailable inhibitors of tumor necrosis factor-alpha converting enzyme (TACE): discovery of indole, benzofuran, imidazopyridine and pyrazolopyridine P1' substituents.
    Lu Z; Ott GR; Anand R; Liu RQ; Covington MB; Vaddi K; Qian M; Newton RC; Christ DD; Trzaskos J; Duan JJ
    Bioorg Med Chem Lett; 2008 Mar; 18(6):1958-62. PubMed ID: 18282708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MMP-13 selective alpha-sulfone hydroxamates: identification of selective P1' amides.
    Fobian YM; Freskos JN; Barta TE; Bedell LJ; Heintz R; Kassab DJ; Kiefer JR; Mischke BV; Molyneaux JM; Mullins P; Munie GE; Becker DP
    Bioorg Med Chem Lett; 2011 May; 21(10):2823-5. PubMed ID: 21493063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Orally active MMP-1 sparing α-tetrahydropyranyl and α-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.
    Becker DP; Barta TE; Bedell LJ; Boehm TL; Bond BR; Carroll J; Carron CP; Decrescenzo GA; Easton AM; Freskos JN; Funckes-Shippy CL; Heron M; Hockerman S; Howard CP; Kiefer JR; Li MH; Mathis KJ; McDonald JJ; Mehta PP; Munie GE; Sunyer T; Swearingen CA; Villamil CI; Welsch D; Williams JM; Yu Y; Yao J
    J Med Chem; 2010 Sep; 53(18):6653-80. PubMed ID: 20726512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and biological evaluation of orally active matrix metalloproteinase inhibitors.
    Hirayama R; Yamamoto M; Tsukida T; Matsuo K; Obata Y; Sakamoto F; Ikeda S
    Bioorg Med Chem; 1997 Apr; 5(4):765-78. PubMed ID: 9158875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-hydroxamate 5-phenylpyrimidine-2,4,6-trione derivatives as selective inhibitors of tumor necrosis factor-alpha converting enzyme.
    Duan JJ; Lu Z; Wasserman ZR; Liu RQ; Covington MB; Decicco CP
    Bioorg Med Chem Lett; 2005 Jun; 15(12):2970-3. PubMed ID: 15908214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.